Oncimmune Holdings PLC
ONC
Company Profile
Business description
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS.
Contact
1 Park Row
MediCity - D6 Building
LeedsLS1 5AB
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2025
Employees
38
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,465.00 | 44.50 | 0.53% |
| CAC 40 | 7,393.76 | 13.02 | 0.18% |
| DAX 40 | 20,024.66 | 115.52 | 0.58% |
| Dow JONES (US) | 42,297.04 | 247.18 | -0.58% |
| FTSE 100 | 8,260.09 | 87.07 | 1.07% |
| HKSE | 19,623.32 | 436.63 | -2.18% |
| NASDAQ | 19,198.96 | 111.83 | -0.58% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,850.25 | 31.38 | -0.53% |
| S&P/ASX 200 | 8,201.20 | 42.10 | 0.52% |
| SSE Composite Index | 3,262.56 | 89.20 | -2.66% |